Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Alendronic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS known ✓ | P14324 | 18/20 | 0.96 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.70 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.52 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.52 |
| ▸ | GGPS1 | O95749 | 7/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Alendronic Acid SCHEMBL5973704 | 1.00 | FDPS (0.96) | FDPSPDE3ALMNAADRB3PDE4D | |
| Alendronic Acid SCHEMBL3388 | 1.00 | FDPS (0.96) | FDPSPDE3ALMNAADRB3PDE4D | |
| Alendronic Acid SCHEMBL204535 | 1.00 | FDPS (0.96) | FDPSPDE3ALMNAADRB3PDE4D | |
| Alendronic Acid SCHEMBL5984073 | 1.00 | FDPS (0.96) | FDPSPDE3ALMNAADRB3PDE4D | |
| Alendronic Acid SCHEMBL3110183 | 1.00 | FDPS (0.96) | FDPSPDE3ALMNAADRB3PDE4D | |
| Alendronic Acid SCHEMBL14840776 | 0.98 | FDPS (0.93) | FDPSPDE3ALMNAADRB3PDE4D | |
| Alendronic Acid SCHEMBL177947 | 0.98 | FDPS (0.93) | FDPSPDE3ALMNAADRB3PDE4D | |
| Alendronic Acid SCHEMBL2282827 | 0.98 | FDPS (0.93) | FDPSPDE3ALMNAADRB3PDE4D | |
| Alendronic Acid SCHEMBL328770 | 0.98 | FDPS (1.00) | FDPSPDE3ALMNAADRB3PDE4D | |
| Alendronic Acid SCHEMBL7749180 | 0.96 | FDPS (0.89) | FDPSPDE3ALMNAADRB3PDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 283 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119818725-A | Polycitrate composite porous bone scaffold and preparation method thereof | 昆明市中医医院 | 2025-04-15 | — | — | CN | claimed |
| CN-118370839-A | Surface charge inversion type amphiphilic platinum prodrug nano-particle and preparation method and application thereof | 中国石油化工股份有限公司 | 2024-07-23 | — | — | CN | claimed |
| CN-116139333-B | Carbon fiber reinforced polyether-ether-ketone composite material and preparation method and application thereof | 吉林大学 | 2024-04-12 | — | — | CN | claimed |
| CN-116139333-A | Carbon fiber reinforced polyether-ether-ketone composite material and preparation method and application thereof | 吉林大学 | 2023-05-23 | — | — | CN | claimed |
| CN-115737837-A | Preparation and application of sulfur dioxide gas and tumor iron death nano therapeutic agent | 南通大学 | 2023-03-07 | — | — | CN | claimed |
| CN-110433667-B | Anti-pollution anti-scaling separation membrane and preparation method thereof | 天津大学 | 2022-03-22 | — | — | CN | claimed |
| EP-2661257-B1 | EFFERVESCENT BISPHOSPHONATE FORMULATIONS | BILGIC MAHMUT (TR) | 2017-11-15 | — | — | EP | claimed |
| CN-104558028-A | Preparation method for alendronate sodium | UNIV HENAN NORMAL | 2015-04-29 | — | — | CN | claimed |
| EP-2661257-A1 | EFFERVESCENT BISPHOSPHONATE FORMULATIONS | Bilgic, Mahmut (TR) | 2013-11-13 | — | — | EP | claimed |
| US-8513010-B2 | Dendritic cells pulsed with a bisphosphonate | MEDINET CO. LTD. (JP) | 2013-08-20 | — | — | US | claimed |
| EP-1865928-A1 | NANOPARTICULATE BIPHOSPHONATE COMPOSITIONS | Elan Pharma International Limited (IE) | 2007-12-19 | — | — | EP | claimed |
| US-20070117781-A1 | Pharmaceutical formulation with improved stability | KONINKLIJKE PHILIPS ELECTRONICS, N.V. (NL) | 2007-05-24 | — | — | US | claimed |
| WO-2006102117-A1 | NANOPARTICULATE BIPHOSPHONATE COMPOSITIONS | ELAN PHARMA INTERNATIONAL LIMITED (IE) | 2006-09-28 | — | — | WO | claimed |
| US-20060210639-A1 | Nanoparticulate bisphosphonate compositions | ELAN PHARMA INTERNATIONAL LIMITED | 2006-09-21 | — | — | US | claimed |
| EP-1680092-A2 | PHARMACEUTICAL FORMULATION WITH IMPROVED STABILITY | Cipla Ltd. (IN) | 2006-07-19 | — | — | EP | claimed |
| US-7011847-B2 | Enteric coated formulation for bisphosphonic acids and salts thereof | U & I PHARMACEUTICALS LTD. (US) | 2006-03-14 | — | — | US | claimed |
| WO-2005030177-A2 | PHARMACEUTICAL FORMULATION WITH IMPROVED STABILITY | CIPLA LIMITED (IN) | 2005-04-07 | — | — | WO | claimed |
| US-20040161460-A1 | Enteric coated formulation for bisphosphonic acids and salts thereof | U & I PHARMACEUTICALS LTD. (US) | 2004-08-19 | — | — | US | claimed |
| US-6676965-B1 | INCREASING RESISTANCE TO STOMACH ACIDIC ENVIRONMENT; AVOIDING RELEASE IN UPPER GASTROINTESTINAL TRACT; REDUCING DISCOMFORT OR ULCERITIS | U&I PHARMACEUTICALS LTD. | 2004-01-13 | — | — | US | claimed |
| WO-2001032185-A1 | A PHARMACEUTICAL COMPOSITION CONTAINING BISPHOSPHONIC ACID(S) OR SALT(S) THEREOF AND A PROCESS OF PREPARING THEREOF | CIPLA LTD. (IN) | 2001-05-10 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060210639-A1 | Nanoparticulate bisphosphonate compositions | ACP3, BPGM, SOST | FDPS 204/4885PDE3A 2306/4885LMNA 3384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.